VolitionRx’s Nu.Q®NETs H3.1 Biomarker: A Game-Changer in Sepsis and Septic Shock
In a groundbreaking development, VolitionRx Limited, a renowned epigenetics company, has recently announced the results of an extensive study revealing that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients. This discovery is expected to revolutionize the diagnosis and treatment of these life-threatening conditions.
About Sepsis and Septic Shock
Sepsis is a potentially life-threatening condition caused by the body’s response to an infection. Septic shock occurs when sepsis progresses to a severe stage where the body’s blood pressure drops, leading to inadequate blood flow to vital organs. Both conditions require immediate medical attention and can result in long-term health complications or even death.
The Study and Its Findings
The large-scale study, conducted in collaboration with researchers from several universities and hospitals, involved over 1,000 sepsis and septic shock patients. The results, published in the prestigious journal Critical Care Medicine, demonstrated that Nu.Q®NETs H3.1 biomarker levels were significantly higher in patients who died within 28 days or required RRT. This correlation held true regardless of other factors such as age, severity of illness, and underlying conditions.
Implications for Patients
This discovery could lead to earlier and more accurate diagnosis of sepsis and septic shock, enabling timely intervention and potentially saving countless lives. With Nu.Q®NETs H3.1 biomarker serving as an independent predictor, doctors could make more informed decisions about patient care and treatment options.
Global Impact
Sepsis and septic shock are leading causes of death worldwide, with an estimated 11 million cases and 189,000 deaths each year. The ability to diagnose these conditions earlier and more accurately could significantly reduce mortality rates and improve patient outcomes. Moreover, this development could lead to cost savings by reducing the need for extensive and costly diagnostic tests and treatments.
Conclusion
VolitionRx’s Nu.Q®NETs H3.1 biomarker has shown great promise in predicting 28-day mortality and need for RRT in sepsis and septic shock patients. This groundbreaking discovery could lead to earlier and more accurate diagnosis, potentially saving countless lives and improving patient outcomes. The implications for individual patients and the global health community are significant and warrant further exploration.
- Sepsis and septic shock are serious conditions that can lead to death or long-term health complications.
- VolitionRx’s Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for RRT in sepsis and septic shock patients.
- Earlier and more accurate diagnosis could lead to timely intervention and improved patient outcomes.
- Global implications include reduced mortality rates and cost savings.
